Memorial Sloan-Kettering Cancer Center
Country not established
- Devices
- 1
What Memorial Sloan-Kettering Cancer Center makes
Memorial Sloan-Kettering Cancer Center develops the MSK-IMPACT, a hybridization-capture-based next-generation sequencing assay designed for comprehensive mutation profiling of actionable cancer targets.
The MSK-IMPACT is classified as a Class II medical device and is listed under the FDA’s 510(k) pathway. The center is based in the United States.
Catalogue
- Regimes: De Novo Registry: De Novo
Frequently asked questions
How many devices does Memorial Sloan-Kettering Cancer Center have in the registry?
The registry currently lists 1 device for Memorial Sloan-Kettering Cancer Center. Devices recorded under merged duplicate company entries are counted once.
Which registries list Memorial Sloan-Kettering Cancer Center's devices?
Among its 1 most recently registered device, Memorial Sloan-Kettering Cancer Center has devices listed in FDA 510(k) (1 device).
What risk classes do Memorial Sloan-Kettering Cancer Center's devices fall under?
Among its 1 most recently registered device, the classes recorded for Memorial Sloan-Kettering Cancer Center's devices are Class II. Each device page shows its own class and authorisation.
What are the newest devices from Memorial Sloan-Kettering Cancer Center in the registry?
The most recently registered devices listed for Memorial Sloan-Kettering Cancer Center include MSK-IMPACT (Integrated Mutation Profiling of Actionable Cancer Targets):a Hybridization-Capture Based Next Generation Sequencing Assay.